UY29824A1 - Preparación de derivados de quinazolinas o sales de los mismos, intermedios utilizados en su preparación y preparación de dichos derivados utilizando esos intermedios - Google Patents
Preparación de derivados de quinazolinas o sales de los mismos, intermedios utilizados en su preparación y preparación de dichos derivados utilizando esos intermediosInfo
- Publication number
- UY29824A1 UY29824A1 UY29824A UY29824A UY29824A1 UY 29824 A1 UY29824 A1 UY 29824A1 UY 29824 A UY29824 A UY 29824A UY 29824 A UY29824 A UY 29824A UY 29824 A1 UY29824 A1 UY 29824A1
- Authority
- UY
- Uruguay
- Prior art keywords
- preparation
- derivatives
- intermediates
- manufacture
- salts
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/16—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
La presente invención se refiere a procedimientos químicos para la fabricación de ciertos derivados de quinazolina, o sales farmacéuticamente aceptables de los mismos. La invención también se refiere un procedimientos para la fabricación de ciertos compuestos intermedios útiles en la fabricación de los derivados de quinazolina y un procedimientos para la fabricación de los derivados de quinazolina utilizando dichos compuestos intermedios. En particular, la presente invención se refiere un procedimientos químicos y compuestos intermedios útiles en la fabricación del compuesto 4-(4-bromo-2-fluoroanilino)-6-metoxi-7-(1-metilpiperidin-4-ilmetoxi)quinazolina.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0519879.1A GB0519879D0 (en) | 2005-09-30 | 2005-09-30 | Chemical process |
Publications (1)
Publication Number | Publication Date |
---|---|
UY29824A1 true UY29824A1 (es) | 2007-04-30 |
Family
ID=35395001
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY29824A UY29824A1 (es) | 2005-09-30 | 2006-09-29 | Preparación de derivados de quinazolinas o sales de los mismos, intermedios utilizados en su preparación y preparación de dichos derivados utilizando esos intermedios |
Country Status (32)
Country | Link |
---|---|
US (8) | US8163926B2 (es) |
EP (2) | EP1943240B1 (es) |
JP (2) | JP5213715B2 (es) |
KR (1) | KR101307641B1 (es) |
CN (3) | CN101277948B (es) |
AR (1) | AR055671A1 (es) |
AT (2) | ATE481399T1 (es) |
AU (1) | AU2006296367B2 (es) |
BR (1) | BRPI0616715A2 (es) |
CA (2) | CA2745829C (es) |
CY (2) | CY1110275T1 (es) |
DE (2) | DE602006017004D1 (es) |
DK (2) | DK1943240T3 (es) |
ES (2) | ES2350513T3 (es) |
GB (1) | GB0519879D0 (es) |
HK (2) | HK1122553A1 (es) |
HR (2) | HRP20100019T1 (es) |
IL (2) | IL190172A (es) |
ME (2) | ME01466B (es) |
MY (2) | MY149834A (es) |
NO (1) | NO342152B1 (es) |
NZ (2) | NZ566566A (es) |
PL (2) | PL2053048T3 (es) |
PT (2) | PT1943240E (es) |
RS (2) | RS51515B (es) |
RU (1) | RU2448102C2 (es) |
SG (1) | SG165416A1 (es) |
SI (2) | SI2053048T1 (es) |
TW (2) | TWI424991B (es) |
UY (1) | UY29824A1 (es) |
WO (1) | WO2007036713A2 (es) |
ZA (1) | ZA200802416B (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7268230B2 (en) * | 2002-02-01 | 2007-09-11 | Astrazeneca Ab | Quinazoline compounds |
GB0519879D0 (en) * | 2005-09-30 | 2005-11-09 | Astrazeneca Ab | Chemical process |
CL2007003158A1 (es) * | 2006-11-02 | 2008-05-16 | Astrazeneca Ab | Procedimiento de preparacion de compuestos derivados de quinazolina o sus sales farmaceuticamente aceptables; compuestos intermediarios; procedimiento de preparacion. |
EP2404595B1 (de) * | 2011-09-01 | 2015-08-05 | Symrise AG | Verfahren zur Herstellung von Indanon-Derivaten |
US9273001B2 (en) * | 2012-08-15 | 2016-03-01 | Glaxo Group Limited | Chemical process |
CN104098544A (zh) * | 2013-04-07 | 2014-10-15 | 浙江九洲药物科技有限公司 | 一种凡德他尼的制备方法 |
CN106397401B (zh) * | 2016-08-30 | 2018-11-13 | 山东罗欣药业集团股份有限公司 | 一种抗癌药物的晶体化合物及其制备方法 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4870083A (en) * | 1987-11-24 | 1989-09-26 | Merrell Dow Pharmaceuticals Inc. | 1,4-Disubstituted-piperidinyl compounds useful as analgesics and muscle relaxants |
JP2829744B2 (ja) | 1989-05-31 | 1998-12-02 | 川研ファインケミカル株式会社 | ピペリジンカルボン酸類の製造方法 |
WO1992006086A1 (en) | 1990-10-01 | 1992-04-16 | Janssen Pharmaceutica N.V. | Novel 4-piperidinylcarbonyl derivatives |
BR9205811A (pt) | 1991-03-28 | 1994-06-28 | Pfizer | Derivados heterociclicos de aminas ciclicas |
CA2102780C (en) | 1991-05-10 | 2007-01-09 | Alfred P. Spada | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase |
US5710158A (en) | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
WO1994019342A1 (en) | 1993-02-18 | 1994-09-01 | Kyowa Hakko Kogyo Co., Ltd. | Adenosine incorporation inhibitor |
EP0700383B1 (en) | 1993-05-26 | 1998-09-23 | Syntex (U.S.A.) Inc. | Novel 1-phenylalkanone 5-ht 4? receptor ligands |
DE4326344A1 (de) | 1993-08-05 | 1995-02-09 | Thomae Gmbh Dr K | Carbonamide, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
AU685212B2 (en) * | 1994-01-13 | 1998-01-15 | Merck Sharp & Dohme Limited | Gem-disubstituted azacyclic tachykinin antagonists |
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
WO1997032856A1 (en) | 1996-03-05 | 1997-09-12 | Zeneca Limited | 4-anilinoquinazoline derivatives |
WO1998010767A2 (en) | 1996-09-13 | 1998-03-19 | Sugen, Inc. | Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders |
GB9718972D0 (en) * | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
IL149034A0 (en) | 1999-11-05 | 2002-11-10 | Astrazeneca Ab | Quinazoline derivatives as vegf inhibitors |
GB0126879D0 (en) | 2001-11-08 | 2002-01-02 | Astrazeneca Ab | Combination therapy |
EP1467995B1 (en) | 2001-12-20 | 2010-05-19 | OSI Pharmaceuticals, Inc. | Pyrrolopyrimidine a2b selective antagonist compounds, their synthesis and use |
US7268230B2 (en) | 2002-02-01 | 2007-09-11 | Astrazeneca Ab | Quinazoline compounds |
JP4389205B2 (ja) | 2002-02-06 | 2009-12-24 | 宇部興産株式会社 | 4−アミノキナゾリン化合物の製法 |
JP2006502132A (ja) | 2002-08-09 | 2006-01-19 | アストラゼネカ アクチボラグ | 癌の治療における血管内皮細胞増殖因子受容体の阻害薬zd6474と放射線療法との併用 |
GB0218526D0 (en) | 2002-08-09 | 2002-09-18 | Astrazeneca Ab | Combination therapy |
GB0223380D0 (en) | 2002-10-09 | 2002-11-13 | Astrazeneca Ab | Combination therapy |
CA2514227C (en) | 2003-02-13 | 2011-08-09 | Astrazeneca Ab | Combination therapy of zd6474 with 5-fu or/and cpt-11 |
KR20060033782A (ko) | 2003-07-10 | 2006-04-19 | 아스트라제네카 아베 | 백금 화합물 및 임의적으로 이온화 방사능과 조합된퀴나졸린 유도체 zd6474의 혈관신생 및/또는 증가된 혈관투과성 관련 질환 치료 용도 |
GB0318423D0 (en) | 2003-08-06 | 2003-09-10 | Astrazeneca Ab | Chemical compounds |
GB0519879D0 (en) * | 2005-09-30 | 2005-11-09 | Astrazeneca Ab | Chemical process |
-
2005
- 2005-09-30 GB GBGB0519879.1A patent/GB0519879D0/en not_active Ceased
-
2006
- 2006-09-27 RS RSP-2010/0520A patent/RS51515B/en unknown
- 2006-09-27 JP JP2008532864A patent/JP5213715B2/ja not_active Expired - Fee Related
- 2006-09-27 WO PCT/GB2006/003587 patent/WO2007036713A2/en active Application Filing
- 2006-09-27 DK DK06794582.4T patent/DK1943240T3/da active
- 2006-09-27 ME MEP-2013-21A patent/ME01466B/me unknown
- 2006-09-27 RS RSP-2010/0037A patent/RS51263B/sr unknown
- 2006-09-27 MY MYPI2011003076A patent/MY149834A/en unknown
- 2006-09-27 CA CA2745829A patent/CA2745829C/en not_active Expired - Fee Related
- 2006-09-27 PT PT06794582T patent/PT1943240E/pt unknown
- 2006-09-27 EP EP06794582A patent/EP1943240B1/en active Active
- 2006-09-27 SI SI200630816T patent/SI2053048T1/sl unknown
- 2006-09-27 CN CN200680036468XA patent/CN101277948B/zh active Active
- 2006-09-27 BR BRPI0616715-2A patent/BRPI0616715A2/pt not_active IP Right Cessation
- 2006-09-27 CA CA2624045A patent/CA2624045C/en not_active Expired - Fee Related
- 2006-09-27 SI SI200630524T patent/SI1943240T1/sl unknown
- 2006-09-27 CN CN201110159628.2A patent/CN102503933B/zh active Active
- 2006-09-27 PT PT09152654T patent/PT2053048E/pt unknown
- 2006-09-27 EP EP09152654A patent/EP2053048B8/en active Active
- 2006-09-27 AT AT09152654T patent/ATE481399T1/de active
- 2006-09-27 NZ NZ566566A patent/NZ566566A/en not_active IP Right Cessation
- 2006-09-27 US US12/088,680 patent/US8163926B2/en active Active
- 2006-09-27 DE DE602006017004T patent/DE602006017004D1/de active Active
- 2006-09-27 DK DK09152654.1T patent/DK2053048T3/da active
- 2006-09-27 AU AU2006296367A patent/AU2006296367B2/en not_active Ceased
- 2006-09-27 AT AT06794582T patent/ATE448218T1/de active
- 2006-09-27 RU RU2008116573/04A patent/RU2448102C2/ru not_active IP Right Cessation
- 2006-09-27 DE DE602006010428T patent/DE602006010428D1/de active Active
- 2006-09-27 SG SG201006940-9A patent/SG165416A1/en unknown
- 2006-09-27 ES ES09152654T patent/ES2350513T3/es active Active
- 2006-09-27 PL PL09152654T patent/PL2053048T3/pl unknown
- 2006-09-27 ES ES06794582T patent/ES2335435T3/es active Active
- 2006-09-27 CN CN201110159729.XA patent/CN102503898B/zh active Active
- 2006-09-27 PL PL06794582T patent/PL1943240T3/pl unknown
- 2006-09-27 ME MEP-2013-51A patent/ME01531B/me unknown
- 2006-09-27 KR KR1020087009317A patent/KR101307641B1/ko active IP Right Grant
- 2006-09-27 NZ NZ593930A patent/NZ593930A/xx not_active IP Right Cessation
- 2006-09-27 MY MYPI20080855A patent/MY145540A/en unknown
- 2006-09-29 AR ARP060104320A patent/AR055671A1/es not_active Application Discontinuation
- 2006-09-29 UY UY29824A patent/UY29824A1/es unknown
- 2006-09-29 TW TW099102690A patent/TWI424991B/zh not_active IP Right Cessation
- 2006-09-29 TW TW095136340A patent/TWI328580B/zh not_active IP Right Cessation
-
2008
- 2008-03-11 NO NO20081267A patent/NO342152B1/no not_active IP Right Cessation
- 2008-03-13 IL IL190172A patent/IL190172A/en not_active IP Right Cessation
- 2008-03-14 ZA ZA200802416A patent/ZA200802416B/xx unknown
- 2008-12-15 HK HK08113582.9A patent/HK1122553A1/xx not_active IP Right Cessation
-
2009
- 2009-09-21 HK HK09108619.5A patent/HK1130478A1/xx not_active IP Right Cessation
-
2010
- 2010-01-11 HR HR20100019T patent/HRP20100019T1/hr unknown
- 2010-01-25 CY CY20101100076T patent/CY1110275T1/el unknown
- 2010-11-12 CY CY20101101019T patent/CY1110887T1/el unknown
- 2010-11-16 HR HR20100620T patent/HRP20100620T1/hr unknown
-
2011
- 2011-12-07 US US13/314,034 patent/US8865899B2/en active Active
-
2012
- 2012-11-28 JP JP2012259782A patent/JP5654546B2/ja not_active Expired - Fee Related
-
2013
- 2013-07-21 IL IL227574A patent/IL227574A/en not_active IP Right Cessation
-
2014
- 2014-09-09 US US14/481,302 patent/US20140378684A1/en not_active Abandoned
-
2015
- 2015-07-22 US US14/805,816 patent/US9815816B2/en active Active
-
2017
- 2017-10-27 US US15/796,615 patent/US10344015B2/en active Active
-
2019
- 2019-05-08 US US16/406,246 patent/US20190263782A1/en not_active Abandoned
-
2020
- 2020-11-02 US US17/086,666 patent/US20220033377A1/en not_active Abandoned
-
2023
- 2023-03-07 US US18/118,549 patent/US20240150317A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY29824A1 (es) | Preparación de derivados de quinazolinas o sales de los mismos, intermedios utilizados en su preparación y preparación de dichos derivados utilizando esos intermedios | |
TW200833667A (en) | Chemical process | |
AR059027A1 (es) | Administracion de inhibidores de dipeptidil peptidasa | |
CL2008003691A1 (es) | Compuestos derivados de 4-(fenil o piridin) pirimidina, inhibidores de la elastasa neutrofila humana; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento y/o la prevencion de hipertension arterial pulmonar, epoc, enfisema pulmonar, entre otras. | |
UY30779A1 (es) | Derivados de dihidropiridina de utilidad como inhibidores de la proteina quinasa | |
ECSP11011469A (es) | Sales de disacarina, ácido difumárico, ácido di-1-hidroxi-2-naftoico y ácido monobenzoico del 2-(4-((2-amino-4-metil-6-(pentilamino)pirimidin-5-il)metil)fenil)acetato de 4-(dimetilamino)butilo | |
PA8680701A1 (es) | Derivados de oxindol | |
ECSP077271A (es) | Derivados de pirimidina | |
NO20081893L (no) | 4-(3-aminopyrazol)pyrimidinderivater til anvendelse som tyrosin-kinaseinhibitorer i behandling av kreft | |
UY32848A (es) | Compuestos heterocíclicos de oxima | |
BR122019010008B8 (pt) | derivados de pirimidina, seu uso, e composição e combinação farmacêuticas | |
ECSP078030A (es) | Formas cristalinas y otras formas de las sales de ácido láctico de 4-amino-5-fluoro-3-[6-(4-metilpiperazin -1-il)-1h-bencimidazol-2 -il]-1h-quinolin-2-ona | |
CL2011002925A1 (es) | Compuestos derivados de isoquinolin-1(2h)-ona, inhibidores selectivos de la actividad de poli (adp-ribosa) polimerasa parp-1; proceso para prepararlos; composicion farmaceutica; y su uso para tratar una enfermedad mediada por la proteina parp-1. | |
BRPI0817843B8 (pt) | inibidores da quinase c-fms, composição farmacêutica que os compreende e processo para a fabricação da dita composição | |
UY29648A1 (es) | Derivados de piridopirimidina, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones | |
ECSP109890A (es) | Particulas de un antagonista de crth2 | |
DE502005008057D1 (de) | Substituierte cyclopenten-verbindungen | |
UA113658C2 (xx) | Кристалічна форма і дималеатного інгібітору тирозинкінази і способи її одержання | |
ECSP088700A (es) | Acidos 4-fenil-tiazol-5-carboxilicos y amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1 | |
CR20110369A (es) | Derivados de quinazolinona útiles como antagonistas de vanilloides | |
ATE481972T1 (de) | Chinazolinon-derivate als vanilloid-antagonisten | |
NZ703549A (en) | Benzodioxole derivative and preparation method and use thereof | |
EA201001517A1 (ru) | Замещенные пиперидины в качестве терапевтических соединений | |
UY30652A1 (es) | N-(2-hidroxietil)-n-metil-4-(quinolin-8-il(1-(tiazol-4-ilmetil)piperidin-4-ilideno)metil)benzamida | |
UY32333A (es) | Derivados cuaternarios de piridina y utilización de los mismos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
DESI | Application deemed to be withdrawn |
Effective date: 20120515 |